Filing Flows › Health Care › iBio (IBIO)
iBio (IBIO) earnings and revenue breakdown
Latest: Q1 FY26 · 10-Q filed Nov 12, 2025 · iBio (IBIO) Q1 FY26 earnings results →
iBio made $100K in Q1 FY26. Operating margin n/m, net loss $5.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 12, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $100K in Q1 FY26, down 50% from the previous quarter.
Operating costs exceeded revenue by $6.0M, an operating margin of -5951.0%. The quarter ended with a net loss of $5.7M, wider than the previous quarter's $5.2M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $108K of depreciation and amortization and $323K of share-based compensation. Working capital and other items used $376K. Capital expenditures of $32K exceeded it, leaving free cash flow of −$5.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY26 | 10-Q | Nov 12, 2025 | $100K | — | n/m | −$5.7M | −$5.7M |
| Q4 FY25 | 10-K | Sep 5, 2025 | $200K | +14% | n/m | −$5.2M | −$4.6M |
| Q2 FY25 | 10-Q | Feb 10, 2025 | $200K | — | n/m | −$4.4M | −$3.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About iBio
iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed at addressing unmet needs by current approved therapies.
In its own words, from its 10-K, filed Aug 28, 2026.
iBio against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IBIO iBio | Q1 FY26 | $100K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: iBio 10-Q on SEC EDGAR · CIK 1420720 · Pharmaceutical Preparations
13F: who owns IBIO and who is buying
More on IBIO
History
Every quarter: Q1 FY26 results · Q4 FY25 results · Q2 FY25 results